Disease · MONDO_0005382

bone Paget disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bone Paget disease. Diseases, record MONDO_0005382. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005382

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bone Paget disease; Open Targets
Open Targets ID: MONDO_0005382; Open Targets
Other names: Paget disease (bone), Paget disease of bone, Paget's bone disease, Paget's disease (bone), Paget's disease of bone, Paget's disease of the bone, Pagets disease (bone), bone Paget's disease, osseous Paget's disease, osteitis deformans; Open Targets
Disease Ontology: DOID:5408; Disease Ontology
NCI Thesaurus: C3292; NCI Thesaurus
Orphanet: ORPHA:280110; Orphanet
Highest stage of its drugs: Approval, for 3 of its 5 drugs, from DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ZOLEDRONIC ACID	CHEMBL4303669	Small molecule	Approval	DailyMed and EMA Human Drugs	9	4	4	Drugs and targets
ALENDRONATE SODIUM	CHEMBL675	Small molecule	Approval	DailyMed	21	0	0	Drugs and targets
CALCITONIN SALMON	CHEMBL3989767	Protein	Approval	FDA	2	0	0	Drugs and targets
RISEDRONIC ACID	CHEMBL923	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ALENDRONIC ACID	CHEMBL870	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FDPS	Farnesyl pyrophosphate synthase	4	Farnesyl diphosphate synthase inhibitor	Approval	https://conductscience.org/library/genes/2224	Drugs and targets
CALCR	Calcitonin receptor	1	Calcitonin receptor agonist	Approval	https://conductscience.org/library/genes/799	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02106455	Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -		315	2019-06-03	Osseous Paget's Disease	RISEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00103740	Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period	Phase 3	185	2012-05-02	Paget's Disease of Bone	RISEDRONIC ACID, ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00051636	Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period	Phase 3	172	2012-05-07	Paget's Disease of Bone	RISEDRONIC ACID, ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00740129	Re-treatment of Participants With Paget's Disease Using Zoledronic Acid	Phase 4	6	2021-05-26	Paget's Disease of the Bone	ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00480662	A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)	Phase 3	60		Paget's Disease of Bone	ALENDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00774020	Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)	Phase 4	9		Paget's Disease of Bone	ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Zoledronic Acid vs Risedronate: serious adverse events	4 of 88	3 of 90	178	NCT00103740	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Patients Who Had Therapeutic Response at 6 Months	84 of 88	67 of 89	177	NCT00103740	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28	8 of 88	1 of 88	176	NCT00103740	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: serious adverse events	5 of 89	8 of 82	171	NCT00051636	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Patients Who Achieve Therapeutic Response at 6 Months.	85 of 88	60 of 82	170	NCT00051636	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28 Relative to Baseline	5 of 88	0 of 82	170	NCT00051636	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period	10 of 78	42 of 63	141	NCT00103740	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Partial Disease Relapse During the Extended Observation Period	9 of 78	37 of 63	141	NCT00103740	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Disease Relapse During the Extended Observation Period	0 of 78	15 of 63	141	NCT00103740	Trial comparisons
Zoledronic Acid and Placebo to Risedronate vs Risedronate and Placebo to Zoledronic Acid: Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period	8 of 75	29 of 52	127	NCT00051636	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24422139	RESULT	1	PubMed
18536953	RESULT	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005382

GET https://conductscience.org/api/diseases/v1/MONDO_0005382/drugs

API reference For AI assistants